Research Site

Fort Sam Houston, Texas 78234

1 studies enrolling now · 9 studies all time

What they study most

COVID-19, Chronic Lymphocytic Leukemia, Diabetes Mellitus, Type 2, Diffuse Large B-Cell Lymphoma, Fallopian Tube Cancer, Heart Failure, Non-Small Cell Lung Cancer, Ovarian Cancer, Primary Peritoneal Cancer, SARS-CoV-2

Studies at this site

• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC — Recruiting now
• A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL — Running, not enrolling
• A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) — Running, not enrolling
• Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL — Running, not enrolling
• Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL — Running, not enrolling
• Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults — Completed
• Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction — Completed
• A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus — Completed
• AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) — Stopped early